Related Experiment Video

Updated: Jun 17, 2026

Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer

Marie-Claude Beauchamp1, Amber Yasmeen, Ariane Knafo

  • 1Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, QC, Canada H3T 1E2.

Journal of Oncology
|January 14, 2010
PubMed

Insights

New research explores the insulin/insulin growth factor (IGF) pathways as a potential therapeutic target for ovarian cancer. Understanding IGF

Area of Science:

  • Gynecologic Oncology
  • Cancer Biology
  • Endocrinology

Background:

  • Ovarian cancer is a lethal gynecological malignancy often diagnosed at advanced stages.
  • Lack of early detection methods and specific symptoms contribute to poor prognosis.
  • High recurrence rates and chemoresistance necessitate novel therapeutic strategies.

Purpose of the Study:

  • To investigate the role of insulin/insulin growth factor (IGF) pathways in ovarian cancer.
  • To evaluate IGF pathways as potential therapeutic targets for ovarian cancer treatment.

Main Methods:

  • Literature review focusing on the involvement of insulin/IGF signaling in ovarian cancer.
  • Analysis of existing research on IGF pathway inhibitors in preclinical and clinical studies.

Main Results:

  • Accumulating evidence suggests the insulin/IGF pathways are implicated in ovarian cancer development and progression.
  • These pathways are frequently dysregulated in ovarian tumors, contributing to tumorigenesis.
  • Preclinical data indicate that targeting IGF pathways may overcome chemoresistance.

Conclusions:

  • The insulin/IGF pathways represent a promising therapeutic target for ovarian cancer.
  • Further research is warranted to develop effective IGF-targeted therapies to improve patient outcomes.
  • Targeting these pathways could offer new hope for patients with recurrent or chemoresistant ovarian cancer.

More Related Videos

Human Ovarian Surface Epithelium Organoids as a Platform to Study Tissue Regeneration07:37

Human Ovarian Surface Epithelium Organoids as a Platform to Study Tissue Regeneration

Published on: August 16, 2024

Ex Vivo Culture of Primary Human Fallopian Tube Epithelial Cells11:46

Ex Vivo Culture of Primary Human Fallopian Tube Epithelial Cells

Published on: May 9, 2011

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...